188 related articles for article (PubMed ID: 32460405)
1. FLT3-ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression.
Soare DS; Radu E; Dumitru I; Popov VM; Bumbea H; Vlădăreanu AM
J Cell Mol Med; 2020 Jul; 24(13):7675-7679. PubMed ID: 32460405
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the
Soare DS; Radu E; Dumitru I; Vlădăreanu AM; Bumbea H
Leuk Lymphoma; 2021 Nov; 62(11):2716-2726. PubMed ID: 34034609
[TBL] [Abstract][Full Text] [Related]
3. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.
Ehninger A; Kramer M; Röllig C; Thiede C; Bornhäuser M; von Bonin M; Wermke M; Feldmann A; Bachmann M; Ehninger G; Oelschlägel U
Blood Cancer J; 2014 Jun; 4(6):e218. PubMed ID: 24927407
[TBL] [Abstract][Full Text] [Related]
4. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
[TBL] [Abstract][Full Text] [Related]
6. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
[TBL] [Abstract][Full Text] [Related]
7. FLT3 Internal Tandem Duplication Mutation, cMPL and CD34 Expressions Predict Low Survival in Acute Myeloid Leukemia Patients.
Ebrahim EK; Assem MM; Amin AI; Kamel MM; El Meligui YM; Metwally AM
Ann Clin Lab Sci; 2016 Dec; 46(6):592-600. PubMed ID: 27993871
[TBL] [Abstract][Full Text] [Related]
8. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
[TBL] [Abstract][Full Text] [Related]
9. FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
Pollard JA; Alonzo TA; Gerbing RB; Woods WG; Lange BJ; Sweetser DA; Radich JP; Bernstein ID; Meshinchi S
Blood; 2006 Oct; 108(8):2764-9. PubMed ID: 16809615
[TBL] [Abstract][Full Text] [Related]
10. Correlation of FLT3 mutations with expression of CD7 in acute myeloid leukemia.
Baqai J; Crisan D
Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):104-8. PubMed ID: 25679063
[TBL] [Abstract][Full Text] [Related]
11. Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication.
Rickmann M; Krauter J; Stamer K; Heuser M; Salguero G; Mischak-Weissinger E; Ganser A; Stripecke R
Ann Hematol; 2011 Sep; 90(9):1047-58. PubMed ID: 21520003
[TBL] [Abstract][Full Text] [Related]
12. FMS-like tyrosine kinase 3 internal tandem duplication and the patterns of its gene sequence in 207 Chinese patients with de novo acute myeloid leukemia.
Zhong L; Jia YQ; Meng WT; Ni X
Arch Pathol Lab Med; 2012 Jan; 136(1):84-9. PubMed ID: 22208491
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations.
Riccioni R; Pelosi E; Riti V; Castelli G; Lo-Coco F; Testa U
Br J Haematol; 2011 Apr; 153(1):33-42. PubMed ID: 21332708
[TBL] [Abstract][Full Text] [Related]
14. RNA-based
Cucchi DGJ; Denys B; Kaspers GJL; Janssen JJWM; Ossenkoppele GJ; de Haas V; Zwaan CM; van den Heuvel-Eibrink MM; Philippé J; Csikós T; Kwidama Z; de Moerloose B; de Bont ESJM; Lissenberg-Witte BI; Zweegman S; Verwer F; Vandepoele K; Schuurhuis GJ; Sonneveld E; Cloos J
Blood; 2018 May; 131(22):2485-2489. PubMed ID: 29669779
[TBL] [Abstract][Full Text] [Related]
15. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
Falini B; Sportoletti P; Brunetti L; Martelli MP
Br J Haematol; 2015 Aug; 170(3):305-22. PubMed ID: 25891481
[TBL] [Abstract][Full Text] [Related]
16. Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia.
De Bellis E; Ottone T; Mercante L; Falconi G; Cugini E; Consalvo MI; Travaglini S; Paterno G; Piciocchi A; Rossi ELL; Gurnari C; Maurillo L; Buccisano F; Arcese W; Voso MT
Leuk Res; 2020 Dec; 99():106462. PubMed ID: 33091616
[TBL] [Abstract][Full Text] [Related]
17. HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression.
Syampurnawati M; Tatsumi E; Furuta K; Takenokuchi M; Nakamachi Y; Kawano S; Kumagai S; Saigo K; Matsui T; Takahashi T; Nagai K; Yabe H; Kondo S; Hayashi Y
Leuk Res; 2007 Jul; 31(7):921-9. PubMed ID: 17056111
[TBL] [Abstract][Full Text] [Related]
18. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
Alachkar H; Santhanam R; Harb JG; Lucas DM; Oaks JJ; Hickey CJ; Pan L; Kinghorn AD; Caligiuri MA; Perrotti D; Byrd JC; Garzon R; Grever MR; Marcucci G
J Hematol Oncol; 2013 Mar; 6():21. PubMed ID: 23497456
[TBL] [Abstract][Full Text] [Related]
19. FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML.
Kivioja J; Malani D; Kumar A; Kontro M; Parsons A; Kallioniemi O; Heckman CA
Sci Rep; 2021 Dec; 11(1):23565. PubMed ID: 34876631
[TBL] [Abstract][Full Text] [Related]
20. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
